Hadassah

Hadassah Drug to Fight Fatty Liver Disease Progressing Well in US Clinical Trials

Thursday, Sep 3 2015

Clinical trials with a Hadassah-developed technology to treat fatty liver disease are moving forward in 25 medical centers, in the United States and Australia. Fatty liver disease, in its severe form—called non-alcoholic steatohepatitis (NASH)—can lead to cirrhosis and liver cancer and there are currently no other treatments available.

Among the US test sites are the Cleveland Clinic (Ohio), Duke Liver Center (Durham, NC), Baylor St. Luke's Medical Center (Houston, Tex), and University of Virginia (Charlottesville). The Australian sites include Westmead Hospital (Sydney) and The Alfred (Melbourne).

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product, being referred to as IMM-124E. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron. See http://www.hadassah.org/news-stories/fda-grants-approval-for-us.html

Immuron has also announced that it is beginning a United States Investor Roadshow, where it will showcase its technology platform and profile to US investment groups. The company reports that its clinical trials “are progressing well” and that “a recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35-40 billion.” The company further explains that “the high prevalence of Type 2 diabetes and obesity, which leads to NASH and other non-alcoholic fatty liver diseases, boosts the prevalence of NASH and its market growth.”

View the Roadshow presentation: http://www.immuron.com/index.php/download_file/-/view/142/

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Feb 7 2019

Six Miscarriages, a Severe Liver Disease, and a Dream

Oshrat Ohana Nagar was a busy newspaper journalist, a self-proclaimed workaholic, and a mother of two children. Shortly after the birth of her second child, however, she began to experience pain throughout her body.

READ MORE ›
alt_text

Wednesday, Feb 6 2019

Hadassah Hematologist Dina Ben-Yehuda: Healer, Researcher, Mentor, and Dean

During this age of big data and artificial intelligence, Prof. Dina Ben-Yehuda, head of the Hadassah Medical Organization’s Department of Hematology and now also the first female dean of the Hadassah-Hebrew University School of Medicine, believes that the “role of physician as healer is more necessary for patients than ever.”

READ MORE ›
alt_text

Wednesday, Feb 6 2019

Hadassah Eye Specialists Take Their Expertise to Nursing Homes

Saving nursing home residents from the burden of commuting to the hospital for eye examinations, Hadassah Medical Organization ophthalmologists and optometrists have begun bringing their expertise to the seniors’ home setting.

READ MORE ›
alt_text

Monday, Feb 4 2019

Hadassah Breast Imaging Specialist Offers Perspective on Preventive Care

The most important adversary to breast cancer screening is fear, says Dr. Tamar Sella, head of the Marlene Greenebaum Multidisciplinary Diagnostic Breast Center at the Hadassah Medical Organization.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More